Table 2.

Exposure to and activity of crossover veliparib monotherapy.

		Progression on carboplatin in the blinded studya		Platinum-free interval at crossover veliparib monotherapy start
	Crossover veliparib monotherapy	Yes	No	<180 days	≥180 days
	(N = 75)	(n = 37)	(n = 38)	(n = 53)	(n = 22)
Mean exposure to crossover veliparib monotherapy, days (range)	154 (2–966)	121.9 (2–539)	196.3 (5–967)	133.7 (2–680)	222.1 (5–967)
Best responseb, n/N (%)
Complete response	0	0	0	0	0
Partial response	8/50 (16)	3/27 (11.1)	5/23 (21.7)	5/37 (13.5)	3/13 (23.1)
Clinical benefit rate at 24 weeksc, % (95% CI)	30.5 (21.9–39.5)	27.3 (13.6–43.0)	46.9 (29.0–62.9)	30.0 (17.7–43.3)	55.0 (29.8–74.5)
Median progression-free survivald, months (95% CI)	2.1 (2.1–4.4)	2.1 (1.9–3.7)	4.4 (2.1–8.2)	2.1 (2.0–4.1)	8.2 (1.9–NR)

Abbreviation: NR, not reached.

^aProgressive disease per protocol indicated as reason for carboplatin discontinuation during placebo plus carboplatin/paclitaxel treatment. All patients receiving crossover veliparib monotherapy were required to have progressed on placebo plus carboplatin/paclitaxel; however, placebo, carboplatin, and paclitaxel could be discontinued independently prior to progression.

^bIncludes patients with at least one measurable lesion at baseline.

^cFrom Kaplan–Meier estimates. Clinical benefit rate is defined as the progression-free rate at 24 weeks (168 days) estimated using Kaplan–Meier methodology.

^dMedian progression-free survival is evaluated from first day of crossover treatment.